Linaclotide Publication Examines Adherence to OTC Constipation Treatment

A new publication concerning linaclotide was released on August 3, 2026. The article, titled "Secretagogue laxatives as a potential strategy to overcome adherence barriers to over-the-counter treatment for clozapine-induced constipation," appeared in The Mental Health Clinician. The publication addresses secretagogue laxatives, a category that includes linaclotide, in the context of adherence barriers associated with over-the-counter treatments for clozapine-induced constipation. This entry reflects only the publication of the article as recorded, without additional data on outcomes or conclusions. No results, efficacy claims, or safety findings are provided in the available event information. The publication is indexed under PubMed ID 42569232 and can be accessed through the associated journal listing. Readers interested in linaclotide's regulatory status or general background can consult the compound overview for further context. This brief reports solely the fact that this publication exists and was catalogued on the stated date, in accordance with the information provided. No further interpretation of the study's content, methodology, or findings is included here, as such details were not part of the supplied event data.